KALBERMATTEN ADAM R 4

What Happened

• Adam R. Kalbermatten, President-Chief Commercial Officer of KORU Medical Systems (KRMD), received three equity awards on 2026-03-17 totaling 157,975 units (45,098; 45,098; and 67,779). Each unit represents a right to receive one share of common stock. All awards were granted at $0.00 (derivative awards), so no cash was paid by the insider.

Key Details

• Transaction date: 2026-03-17; Form 4 filed 2026-03-18 (appears timely).
• Grants: 45,098 units; 45,098 units; 67,779 units — total 157,975 units; reported price $0.00 (derivative awards).
• Shares owned after transaction: not specified in the summary filing.
• Vesting and performance notes:
  • F1: Each unit = right to one common share on applicable vesting date.
  • F2: Some units vest in equal increments on March 17, 2027 and each of the next three anniversaries.
  • F3: Certain units vest only if performance targets are met as of Dec 31, 2028; reported amount is the target (0%–150% payout range). Those performance units vest at 100% upon a change in control before 12/31/2028.
• Filing remark: includes standard disclaimer that the filer is not necessarily admitting beneficial ownership; Power of Attorney previously filed.

Context

• These are grant/award (derivative) transactions, not open-market purchases or sales — they do not generate immediate cash for the insider nor indicate an immediate sale of shares. Performance-based components mean the final number of shares earned could be higher or lower than the target reported. Such awards are commonly used for retention and incentive compensation; they should be interpreted as part of executive pay rather than a direct market bet.